Bill Maughan
Stock Analyst at Canaccord Genuity
(1.32)
# 2,494
Out of 4,479 analysts
17
Total ratings
9.09%
Success rate
-3.4%
Average return
Main Sectors:
Top Industries:
9 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTX Nkarta | Maintains: Buy | $16 → $15 | $5.85 | +156.41% | 2 | May 10, 2024 | |
| FATE Fate Therapeutics | Maintains: Buy | $11 → $9 | $3.26 | +176.07% | 1 | May 10, 2024 | |
| IMCR Immunocore Holdings | Maintains: Hold | $63 → $67 | $36.43 | +83.91% | 3 | May 9, 2024 | |
| MRNA Moderna | Maintains: Hold | $91 → $106 | $115.95 | -8.58% | 3 | May 3, 2024 | |
| BNTX BioNTech SE | Reiterates: Buy | $171 | $78.83 | +116.92% | 4 | Mar 21, 2024 | |
| IPSC Century Therapeutics | Maintains: Buy | $22 → $24 | $2.41 | +895.85% | 1 | Mar 15, 2024 | |
| YMAB Y-mAbs Therapeutics | Maintains: Buy | $22 → $26 | $11.83 | +119.78% | 1 | Mar 4, 2024 | |
| BCYC Bicycle Therapeutics | Reiterates: Buy | $60 | $20.29 | +195.71% | 1 | Feb 21, 2024 | |
| MRUS Merus | Initiates: Buy | $45 | $54.45 | -17.36% | 1 | Nov 2, 2023 |
Nkarta
May 10, 2024
Maintains: Buy
Price Target: $16 → $15
Current: $5.85
Upside: +156.41%
Fate Therapeutics
May 10, 2024
Maintains: Buy
Price Target: $11 → $9
Current: $3.26
Upside: +176.07%
Immunocore Holdings
May 9, 2024
Maintains: Hold
Price Target: $63 → $67
Current: $36.43
Upside: +83.91%
Moderna
May 3, 2024
Maintains: Hold
Price Target: $91 → $106
Current: $115.95
Upside: -8.58%
BioNTech SE
Mar 21, 2024
Reiterates: Buy
Price Target: $171
Current: $78.83
Upside: +116.92%
Century Therapeutics
Mar 15, 2024
Maintains: Buy
Price Target: $22 → $24
Current: $2.41
Upside: +895.85%
Y-mAbs Therapeutics
Mar 4, 2024
Maintains: Buy
Price Target: $22 → $26
Current: $11.83
Upside: +119.78%
Bicycle Therapeutics
Feb 21, 2024
Reiterates: Buy
Price Target: $60
Current: $20.29
Upside: +195.71%
Merus
Nov 2, 2023
Initiates: Buy
Price Target: $45
Current: $54.45
Upside: -17.36%